Semaglutide for Type 2 Diabetes

(GLOW Trial)

This trial explores the effects of a diabetes medication called semaglutide on muscle and bone health in older women with type 2 diabetes. Researchers aim to determine if using this treatment for six months can improve muscle strength. Participants will receive semaglutide as part of their regular care and will undergo tests such as hand grip strength assessments and bone scans. Women over 65 with type 2 diabetes who do not have osteoporosis or other serious health conditions may be eligible to join. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to contribute to important research that could lead to new treatment options.

The trial does not specify if you need to stop your current medications, but you cannot participate if you've used certain diabetes medications like GLP-1RA, GIP analogues, pioglitazones, or DPP-4 inhibitors in the last 6 months. It's best to discuss your current medications with the trial team.

A previous study found semaglutide safe for people with type 2 diabetes, with most tolerating it well. Some experienced mild side effects like nausea and diarrhea, common with this type of treatment, while serious problems were rare.

Another study showed that semaglutide might slightly increase heart rate in about 16% of people over two years. However, it also reduces the risk of major heart issues, so the benefits often outweigh the risks.

Semaglutide is unique because it is a GLP-1 receptor agonist, which offers a different approach compared to traditional type 2 diabetes treatments like metformin or sulfonylureas. Unlike these standard options, semaglutide not only helps in lowering blood sugar but also has been shown to aid in weight loss and improve heart health. Researchers are excited about semaglutide because it provides a dual benefit of managing blood sugar levels while also potentially reducing cardiovascular risks, which is a major concern for people with type 2 diabetes.

Research has shown that semaglutide effectively manages type 2 diabetes and aids in weight loss. Many patients experience significant weight loss, with some losing more than 15% of their body weight. It also helps control blood sugar levels, with nearly half of the users reaching a healthy range. Additionally, semaglutide may reduce heart-related risks, which is crucial for people with diabetes. These benefits suggest that semaglutide could improve overall health and fitness, especially in older adults. Participants in this trial will receive semaglutide as part of their routine clinical care. The study will observe metabolic, musculoskeletal, and functional changes associated with ongoing therapy over a 6-month period.³⁶⁷⁸⁹